IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies

Passalacqua, Giovanni; Mincarini, Marcello; Colombo, Daniele; Troisi, Giuseppe; Ferrari, Marta; Bagnasco, Diego; Balbi, Francesco; Riccio, Anna Maria; Canonica, Giorgio Walter

doi:10.1016/j.pupt.2017.05.007

Cited by 67 publications

(47 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Especially for the expensive biological agents proposed for severe asthma, real-life observations could help in refining the prescription criteria and improving the use of resources. A composite index including different biomarkers may represent a potential tool in order to better predict the response to these drugs as suggested, for instance, in COPD [38] and in Idiopathic Pulmonary Fibrosis [39]. All data has been reported as mean and standard deviation, where not otherwise specified.…”

Section: Discussionmentioning

confidence: 99%

One year of mepolizumab. Efficacy and safety in real-life in Italy

Bagnasco

Caminati

Menzella

et al. 2019

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

One year of mepolizumab. Efficacy and safety in real-life in Italy

Bagnasco

Caminati

Menzella

et al. 2019

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

“…In addition, we also examined the expression levels of several cytokines that are important in the PF model. The IL-12 20 , IL-4 and IL-13 21 are generally upregulated in the lung tissue of mice with BLM-induced PF. However, it is worth considering whether our experimental results were not consistent with the literature reports.…”

Section: The Expression Of Cytokines Related To the Pf Modelmentioning

confidence: 96%

Establishment of the trans-resveratrol-induced mouse pulmonary fibrosis model and its comparison with the bleomycin-induced model

Yiwen

Chenzhong

et al. 2019

Preprint

View full text Add to dashboard Cite

Pulmonary fibrosis (PF) is a progressive, fatal disease, and its pathogenic mechanism has not yet been identified. The bleomycin (BLM)-induced animal model has several shortcomings that cannot be overcome.We accidentally found that the continuous oral administration of trans-resveratrol (TR) at levels above the prescribed dose can induce PF within a certain period of time, and this model can be successfully replicated in mice, as indicated by the hydroxyproline (HYP) test and pathological analysis. The TR model requires no anesthesia or surgery and thus causes less damage to mice than the BLM model. The progress of fibrosis in the TR model was slow but progressed steadily compared with the BLM model, and the TR model was more comparable to human PF. Although the pathogenesis is not understood, the TR-induced PF model indicated that there may be a close relationship between PF and tumors and antitumor drugs, which requires further exploration.

show abstract

“…In animal models, inducible pulmonary overexpression of IL-13 causes alveolar airspace enlargement, increased lung compliance, and mucus metaplasia (18,19), characteristics usually associated with an emphysema phenotype. IL-13 signaling has also been shown to be involved in tissue fibrosis (20), where it appears to activate fibroblast proliferation and extracellular matrix deposition through transforming growth factor-β (TGF-β) production (20)(21)(22). Surprisingly, given the strong evidence supporting a role for IL-13 in alveolar biology and disease, the effect of IL-13 on alveolar epithelial stem cell function and response to injury has not been previously studied.…”

Section: Introductionmentioning

confidence: 99%